🎯
LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$9926.HK
AKESO
CHINAFREE PREVIEW
AVG HISTORICAL GAP-5.78%
MAX GAP RECORD-6.13%
PREMIUM
AI ACCURACY RATE92.4%
Unlock AI Insights 🔓LAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $9926.HK
EXECUTIONS0
WIN RATE••.•%
NET ROI+•••.••%
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| RADAR SCANNING: WAITING FOR NEXT CATALYST | ||||||
🔒 Institutional Data Protected
UNLOCK FULL BLOTTERExact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
AVG VOLATILITY5.8%
Bullish Gaps
Bearish Gaps
Neutral
Intelligence Brief
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and… Read full dossier
CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL